Erlotinib for the Treatment of Non-Small-Cell Lung Cancer (TA162)

Technology Appraisal Guidance No. 162

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Erlotinib is recommended, within its licensed indication, as an alternative to docetaxel as a second-line treatment option for patients with non-small-cell lung cancer (NSCLC) only on the basis that it is provided by the manufacturer at an overall treatment cost (including administration, adverse events and monitoring costs) equal to that of docetaxel.

1.2 The decision to use erlotinib or docetaxel (as outlined in section 1.1) should be made after a discussion between the responsible clinician and the individual about the potential benefits and adverse effects of each treatment.

1.3 Erlotinib is not recommended for the second-line treatment of locally advanced or metastatic NSCLC in patients for whom docetaxel is unsuitable (that is, where there is intolerance of or contraindications to docetaxel) or for third-line treatment after docetaxel therapy.

1.4 People currently receiving treatment with erlotinib, but for whom treatment would not be recommended according to section 1.3, should have the option to continue treatment until they and their clinicians consider it appropriate to stop.


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at NICE.

An abridged version of this guidance (a 'quick reference guide') is also available. Printed copies of the quick reference guide can be obtained by contacting 0845 003 7783 or emailing publications@nice.org.uk and quoting reference number N1737. It is also available on the Internet at NICE.

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Erlotinib for the Treatment of Non-Small-Cell Lung Cancer.
Issue Date: November 2008
Review Date: June 2010


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in